4. Timing of post-abortion contraception
|
|
- Loreen O’Connor’
- 5 years ago
- Views:
Transcription
1 Web annexes: Medical management of abortion: evidence summary* 4. Timing of post-abortion contraception * This publication forms part of the WHO guideline entitled Medical Management of Abortion. The full guideline and other web annexes are available at: 1
2 WHO/RHR/18.37 World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Medical management of abortion: evidence base for timing of post-abortion contraception. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at Sales, rights and licensing. To purchase WHO publications, see To submit requests for commercial use and queries on rights and licensing, see Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is bei ng distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. 2
3 Contents Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD)... 1 Comparison 1: Immediate (after mifepristone administration) compared with delayed (at or after follow-up visit) initiation of hormonal contraception: implant... 1 Summary of Findings table for Comparison Forest plots for Comparison Comparison 2: Immediate (after mifepristone administration) compared with delayed (at or after follow-up visit) initiation of hormonal contraception: depot medroxyprogesterone acetate (DMPA)... 6 Summary of Findings table for Comparison Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement... 1 Comparison: Placement of an IUD at a follow-up visit compared with placement of an IUD at an interval visit after medical abortion regimens... 1 Summary of Findings table for Comparison... 1 Forest plots for Comparison
4 Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) Comparison 1: Immediate (after mifepristone administration) compared with delayed (at or after follow-up visit) initiation of hormonal contraception: implant Summary of Findings table for Comparison 1 Outcome Anticipated absolute effect * (95% CI) Relative effect Risk with delayed Risk with immediate (95% CI) initiation of initiation of contraceptive contraceptive implant implant Efficacy: ongoing pregnancy 8 per per 1000 (1 60) Efficacy: any treatment, medical or surgical, to complete abortion b Efficacy: completed without surgical intervention Efficacy: contraceptive effectiveness, including unintended pregnancy (failure) Safety: serious adverse events; assessed by hospitalization, transfusion, surgery beyond uterine aspiration, death Side-effects: additional abortion procedures needed due to bleeding (minor) 82 per per 1000 (66 145) 950 per per 1000 ( ) 32 per per 1000 (2 20) g RR 1.02 ( ) RR ( ) RR 0.99 ( ) RR ( ) g No. of participants (studies) Certainty of the evidence (GRADE) 1 LOW a VERY LOW c,d LOW e,f LOW h Comment Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect No direct evidence identified Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect No direct evidence identified No direct evidence identified Bleeding is reported either as duration of bleeding and proportion with heavier bleeding than heavy period or implant removal due to bleeding No study provided detailed information about additional medical or surgical abortion procedures required due to heavy bleeding 1 Grading of Recommendations Assessment, Dev elopment and Ev aluation more information: w w.gradeworkinggroup.org Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 1
5 Outcome Anticipated absolute effect * (95% CI) Relative effect Risk with delayed Risk with immediate (95% CI) initiation of initiation of contraceptive contraceptive implant implant Side-effects: contraception discontinued due to bleeding (minor) Side-effects: pain/abortion-related pain Acceptability of immediate contraception before abortion (i.e. not disappointed with assignment; rated as pleased or neutral); assessed by patient report Acceptability of contraception at 6 months (very satisfied, fairly satisfied, plus neither dissatisfied nor satisfied); assessed by patient report Continuation rates of implant at 6 months 42 per per 1000 (19 97) 479 per 1000 j 521 per 1000 ( ) j 875 per per 1000 ( ) 467 per per 1000 ( ) 669 per per 1000 ( ) RR 1.03 ( ) RR 1.09 ( ) j RR ( ) RR 1.28 ( ) RR 1.17 ( ) No. of participants (studies) 538 (1 RCT) (1 RCT) Certainty of the evidence (GRADE) 1 VERY LOW d,i VERY LOW d,k LOW l VERY LOW i,m VERY LOW i,n Comment No direct evidence identified CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Hognert et al. 2 measured pain but did not report pain by group Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence High certainty: We are very confident that the true effect is close to the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of th e effect. Very low certainty: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. Explanations a. 95% CI for surgery to complete abortion and any extra surgical or medical treatment to complete abortion include both appreciable benefit and harm. b. Includes surgery for ongoing pregnancy, surgeries for other reasons, and additional medical treatment. No details provided fo r nature or reason of other surgeries. c. Moderate risk for one study and low for the other. d. Downgraded by two: (1) 95% CI crosses 1 and (2) total number of events is < 300. e % attrition in one study, low in other. f. 95% CI crosses 1. g. Intention to treat (ITT) not performed. They excluded women who did not have 6 months of follow-up or those who were followed up but were missing pregnancy data. The denominator we use is the number originally randomized (ITT) and our CI assumes both worst case and best case scenarios (e.g. all excluded either did not become pregnant or all became pregnant). Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 2
6 h. Concern about outcome assessment: pregnancy at 6 months (contraceptive failure) was defined by the patient not actively reporting being pregnant (self-report) resulting in issues both of accuracy as it relates to pregnancy status early in pregnancy and the need to actively report the pregnancy for it to be coun ted. i. High attrition approximately 30% attrition in immediate and 43% attrition in delayed. j. Measured on scale of 0 10; scores of 8 or higher were considered to be severe. k. Outcome measures not described in protocol; or methods rating scale using 0 10, but categorized as 7 or less, 8 or greater; or missing. l. Concern about high attrition 28% immediate and 36% delayed at 6 months; no blinding of outcome assessment. m. Event rate is < 300 cases. n. Loss to follow-up between % in immediate and % in delayed groups. References 1. Raymond EG, Weaver MA, Tan YL, Louie KS, Bousiéguez M, Lugo-Hernández EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol. 2016;127(2): Hognert H, Kopp Kallner H, Cameron S, Nyrelli C, Jawad I, Heller R, et al. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion a randomized controlled equivalence trial. Hum Reprod. 2016;31(11): Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 3
7 Forest plots for Comparison 1 Analysis 1. Efficacy: additional procedures to complete abortion Analysis 2. Efficacy: completion without surgical intervention Analysis 3. Efficacy: contraceptive effectiveness immediate versus delayed implant Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 4
8 Analysis 4. Continuation rates of implant at 6 months Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 5
9 Comparison 2: Immediate (after mifepristone administration) compared with delayed (at or after follow-up visit) initiation of hormonal contraception: depot medroxyprogesterone acetate (DMPA) Summary of Findings table for Comparison 2 Outcome Anticipated absolute effect * (95% CI) Relative effect Risk with delayed Risk with immediate (95% CI) initiation of DMPA initiation of DMPA Efficacy: ongoing pregnancy 8 per per 1000 (8 166) Efficacy: additional procedures to complete abortion Efficacy: completed without surgical intervention Efficacy: contraceptive effectiveness immediate vs delayed (failure) Safety: serious adverse events; assessed by hospitalization, transfusion, surgery beyond uterine aspiration, death Side-effects: additional abortion procedures due to bleeding (minor) Side-effects: discontinued contraception due to bleeding (minor) Side-effects: pain/abortion-related pain 114 per per 1000 (70 192) 51 per per 1000 (29 132) 30 per 1000 c 22 per 1000 (7 69) c RR 4.20 ( ) RR 1.01 ( ) RR 1.22 ( ) RR 0.75 ( ) c No. of participants (studies) ,c Certainty of the evidence (GRADE) LOW a LOW b LOW b VERY LOW b,d,e Comment Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect No direct evidence identified Our confidence in the direct estimate is limited; the true effect may be substantially different from the estimate of the effect No direct evidence identified No direct evidence identified Bleeding is reported either as duration of bleeding or proportion with heavier bleeding than heavy period No detailed information provided about additional medical or surgical abortion procedures required due to heavy bleeding No direct evidence identified 445 per 1000 f 467 per 1000 ( ) f RR 1.05 ( ) f 461 VERY LOW b,g Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 6
10 Outcome Anticipated absolute effect * (95% CI) Relative effect Risk with delayed Risk with immediate (95% CI) initiation of DMPA initiation of DMPA Acceptability of immediate contraception before abortion (i.e. not disappointed with assignment; rated as pleased or neutral); assessed by patient report 890 per per 1000 ( ) RR 1.10 ( ) No. of participants (studies) 461 Certainty of the evidence (GRADE) VERY LOW b,d,h Comment CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Not defined in methods or protocol Data related to whether participants are not disappointed (i.e. neutral or pleased) with assignment, prior to abortion or contraception GRADE Working Group grades of evidence High certainty: We are very confident that the true effect is close to the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. Explanations a. 95% CI for surgery to complete abortion and any extra surgical or medical treatment to complete abortion include both appreci able benefit and harm. b. Downgraded by two: (1) 95% CI includes both possible harm and possible benefit; and (2) total number of events is < 300. c. Intention to treat (ITT) not performed. They excluded women who did not have 6 months of follow-up or those who were followed up but were missing pregnancy data. The denominator we use is the number originally randomized (ITT) and our CI assumes both worst case and best case scenarios (e.g. all excluded either did not become pregnant or all became pregnant). d. Outcome measure not described in methods of paper nor in registered protocol. Data presented in abstract indi cates satisfaction with group assignment. e. Concern about outcome assessment: pregnancy at 6 months (contraceptive failure) was defined by the patient not actively reporting being pregnant (self-report) resulting in issues both of accuracy as it relates to pregnancy status early in pregnancy and the need to actively report the pregnancy for it to be counted. f. Measured on scale of 0 10; scores of 8 or higher were considered to be severe. g. Outcome measures intent and assessment not reported in registered protocol or methods. h. Outcome measure is satisfaction with group assignment in the study. Unclear whether this is driven by satisfaction with abortion, contraception, study follow-up or other study-related differences in the groups. No description is provided in either of two related studies or their protocols to understand how this was asked. Also patients were significantly different at baseline which was more dramatic than the change in groups over time. This is not accounted for. Reference 1. Raymond EG, Weaver MA, Louie KS, Tan YL, Bousiéguez M, Aranguré-Peraza AG, et al. Effects of depot medroxyprogesterone acetate injection timing on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol. 2016;127(2): Recommendation 4a: Timing of post-abortion hormonal contraception initiation, except for intrauterine device (IUD) 7
11 Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement Comparison: Placement of an IUD at a follow-up visit compared with placement of an IUD at an interval visit after medical abortion regimens Summary of Findings table for Comparison Outcome Anticipated absolute effect * (95% CI) Relative effect Risk with delayed Risk with immediate (95% CI) initiation of an IUD placement of an IUD (3 6 weeks after (5 7 days after mifepristone) mifepristone) Efficacy: contraceptive effectiveness including unintended pregnancy at 6 months Efficacy: contraceptive effectiveness including unintended pregnancy at 12 months Efficacy: need for further intervention (uterine evacuation) post-iud placement due to retained tissue/bleeding (efficacy of medical abortion) Safety: post-iud placement infection 27 per per 1000 (0 60) 120 per per 1000 (18 111) 0 per per 1000 (0 0) 77 per per 1000 (46 191) Safety: perforation 6 months 0 per per 1000 (0 0) Safety: perforation 12 months 0 per per 1000 (0 0) Safety: expulsion at 6 months 92 per per 1000 (50 224) Safety: expulsion at 12 months 38 per per 1000 (0 0) RR 0.12 ( ) RR 0.37 ( ) RR ( ) RR 1.21 ( ) RR 0.91 ( ) RR 0.87 ( ) RR 1.14 ( ) RR 0.48 ( ) No. of participants (studies) (1 RCT) (3 RCTs) (2 RCTs) 1, (1 RCT) (1 RCT) 3 5 Certainty of the evidence (GRADE) LOW a,b VERY LOW b,c LOW b,d,e LOW b,c,f h LOW a,b VERY LOW b,c LOW a,b VERY LOW b,c Comment We are uncertain about the effect of this outcome because the certainty of the evidence is low We are uncertain about the effect of this outcome because the certainty of the evidence is very low because the certainty of the evidence is low because the certainty of the evidence is low because the certainty of the evidence is low because the certainty of the evidence is very low because the certainty of the evidence is low because the certainty of the evidence is very low Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement 1
12 Safety: bleeding post-iud resulting in additional procedures Safety: death 0 per per 1000 (0 0) Side-effects: bleeding, contraception discontinued Side-effects: pain at IUD insertion (scale 0 10) Acceptability of/satisfaction with IUD Continuation rates of IUD at 6 months Continuation rates of IUD at 12 months Overlaps with need for further intervention post- IUD No events reported Korjamo et al. 4,5 reports bleeding problems defined as additional contact or an intervention needed but they did not differentiate between the two RR 1.03 ( ) 558 (3 RCTs) 1 5 VERY LOW b,c,i because the certainty of the evidence is very low Unable to derive GRADE outcome as either not reported or not disaggregated per group The mean side-effects pain at IUD insertion was 0 The mean side-effects pain at IUD insertion in the intervention group was 0 (0 0) 90 (1 RCT) 4 MODERATE j There is probably little or no difference in the pain experienced with IUD insertion when initiation is immediate or delayed following medical abortion for gestations up 63 days No direct evidence identified 608 per per 1000 ( ) 391 per per 1000 ( ) RR 1.09 ( ) RR 1.58 ( ) (1 RCT) 3 MODERATE a,i VERY LOW c,h CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). There may be little or no difference in the continuation rate of IUD use at 6 months between women who received immediate versus delayed IUD insertion post-medical abortion because the certainty of the evidence is very low GRADE Working Group grades of evidence High certainty: We are very confident that the true effect is close to the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of e ffect. Explanations a. Risk of bias: downgraded 1: loss to follow-up variable but one study had 24% in delayed placement group. b. Imprecision: downgraded 1 level as studies are relatively small and outcome is an example of a rare event. c. Risk of bias: downgraded 2 levels as loss to follow-up is > 20% in one study. d. Risk of bias: no downgrade: duration of time of follow up is variable across studies (6 versus 12 months); although assuming that need for an intervention either for retained tissue due to the medical abortion following IUD placement would occur within several months postplacement and all studies reported over this time period. Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement 2
13 e. Risk of bias: downgraded 2 levels: studies varied in exclusion of subjects who needed uterine evacuation prior to IUD insertion. All studies utilized ultrasound to dete rmine if ongoing pregnancy, missed abortion, or thick endometrium triggering evacuation occurred prior to IUD placement. Thus, interventions were already performed prior to IUD placement in all studies making it unlikely of an intervention being necessary post-iud placement. f. Risk of bias: downgraded 1 level: one study enrolled women with lower risk of women as routine sexually transmitted infection (STI) screening occurred. g. Risk of bias: no downgrade: duration of time to determine outcome is variable across studies; although assumption would be that likely infection due to post-medical abortion/iud would occur within several months post-procedure and all studies reported over this time period. h. Inconsistency: no downgrade: only one study accounted for all of the infections reported. i. Risk of bias: no downgrade: duration of time of follow up to determine outcome is variable across studies; although assumption would be that likely a death due to medical abortion and IUD placement would occur within several months post-procedure and all studies reported over this time period. j. Inconsistency: downgraded 1 level: only one study provided pain at insertion data that could be summarized in GRADE format. References 1. Saav I, Stephansson O, Gemzell Danielsson K. Early versus delayed insertion of intrauterine contraception after medical abortion a randomized controlled trial. PLoS One. 2012;7(11):e Shimoni N, Davis A, Ramos ME, Rosario L, Westhoff C. Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial. Obstet Gynecol. 2011;118(3): Korjamo R, Mentula M, Heikinheimo O. Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy 1 year continuation rates: a randomised controlled trial. BJOG. 2017;124(13): Korjamo R, Mentula M, Heikinheimo O. Fast-track vs. delayed insertion of the levonorgestrel-releasing intrauterine system after early medical abortion: a randomized trial. Contraception. 2017;96(5): Korjamo R, Mentula M, Heikinheimo O. Expulsions and adverse events following immediate and later insertion of a levonorgestre l releasing intrauterine system after medical termination of late first- and second-trimester pregnancy: a randomised controlled trial. BJOG. 2017;124(13): Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement 3
14 Forest plots for Comparison Analysis 1. Efficacy: contraceptive effectiveness at 6 months Analysis 2. Safety: infection Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement 4
15 Analysis 3. Safety: expulsion at 6 months Analysis 4. Continuation rate at 6 months Recommendation 4b: Timing of post-abortion intrauterine device (IUD) placement 5
GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND
GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND 48+ MONTHS DECEMBER 2017 Guidance For Sampling ART
More informationLatent tuberculosis infection
Latent tuberculosis infection Updated and consolidated guidelines for programmatic management ANNEX 3 Values and preferences for the management of latent tuberculosis infection: survey of populations affected
More informationBEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA
BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA THIS DOCUMENT IS A SUPPLEMENT TO BEST PRACTICES IN MICROPLANNING FOR POLIO ERADICATION. ACKNOWLEDGEMENTS
More informationRaising tobacco taxes in Bangladesh in FY : An opportunity for development
Raising tobacco taxes in Bangladesh in FY 2018-2019: An opportunity for development Raising tobacco taxes would: Generate extra revenues between BDT 75 billion and 100 billion. Reduce the number of current
More informationLatent tuberculosis infection
Latent tuberculosis infection Updated and consolidated guidelines for programmatic management ANNEX 2 Evidence-to-Decision and GRADE tables Latent tuberculosis infection Updated and consolidated guidelines
More informationWEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV
WEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV In: Updated recommendations on first-line and second-line antiretroviral regimens and
More informationWHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,
WHO/NMH/PND/7.4 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 207 Monitoring tobacco use and prevention policies Executive summary fresh and alive World Health Organization 207 Some rights reserved. This
More informationSummary report on the WHO-EM/WRH/104/E
Summary report on the Training of trainers course for national gynaecology and obstetrics societies and midwifery associations on evidence-based guidelines for strengthening family planning services WHO-EM/WRH/104/E
More informationBEST PRACTICES FOR PLANNING A VACCINATION CAMPAIGN FOR AN ENTIRE POPULATION
PLANNING A VACCINATION CAMPAIGN FOR AN ENTIRE POPULATION THIS DOCUMENT IS A SUPPLEMENT TO BEST PRACTICES IN MICROPLANNING FOR POLIO ERADICATION. ACKNOWLEDGEMENTS These best practices documents for polio
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES 2016 UPDATE Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care
More informationWeb Annex 3.1. Adult hepatitis C virus treatment systematic review
Web Annex 3.. Adult hepatitis C virus treatment systematic review Michael Zoratti, Hamilton, Canada In: Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection
More informationSummary report on the WHO-EM/CSR/124/E
Summary report on the Consultative workshop to define an appropriate surveillance strategy for detection of clusters of Zika virus infection and other arboviral diseases using both syndromic- and event-based
More informationpreventing suicide Regional strategy on
Over 800 000 people die due to suicide every year and there are many more who attempt suicide. Suicide was the second leading cause of death among 15-29 year olds globally in 2012. 75% of global suicide
More informationWHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION
MODULE 11 PrEP USERS WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION JULY 2017 WHO/HIV/2017.31 World Health Organization 2017 Some rights reserved. This work is available under
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationOperational Guidance on Sharing Seasonal Influenza viruses with WHO Collaborating Centres (CCs) under the Global Influenza Surveillance and Response
Operational Guidance on Sharing Seasonal Influenza viruses with WHO Collaborating Centres (CCs) under the Global Influenza Surveillance and Response System (GISRS) 31 October 2017 WHO/WHE/IHM/GIP/2017.6
More informationState of InequalIty. Reproductive, maternal, newborn and child health. executi ve S ummary
State of InequalIty Reproductive, maternal, newborn and child health executi ve S ummary WHO/HIS/HSI/2015.2 World Health Organization 2015 All rights reserved. Publications of the World Health Organization
More informationGOOD PHARMACOPOEIAL PRACTICES
May 2013 RESTRICTED GOOD PHARMACOPOEIAL PRACTICES CONCEPT PAPER ON PURPOSE AND BENEFITS (MAY 2013) DRAFT FOR COMMENT Please address any comments on this proposal by 12 July 2013 to Dr S. Kopp, Medicines
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for
More informationGuidelines for treatment of drug-susceptible tuberculosis and patient care
TREATMENT OF TUBERCULOSIS Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017 UPDATE Annex 4 EVIDENCE-TO-DECISION TABLES TREATMENT OF TUBERCULOSIS Guidelines for treatment
More informationRevision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)
August 2008 RESTRICTED MEBENDAZOLE Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008) REVISED DRAFT FOR ADOPTION This document was provided by a quality control
More informationMONITORING HEALTH INEQUALITY
MONITORING HEALTH INEQUALITY An essential step for achieving health equity ILLUSTRATIONS OF FUNDAMENTAL CONCEPTS The examples in this publication draw from the topic of reproductive, maternal and child
More informationChecklist for assessing the gender responsiveness of sexual and reproductive health policies. Pilot document for adaptation to national contexts
Checklist for assessing the gender responsiveness of sexual and reproductive health policies Pilot document for adaptation to national contexts Address requests about publications of the WHO Regional Office
More informationSeasonal Influenza. Zoonotic Influenza. Pandemic Influenza
Seasonal Pandemic Frequently Asked Questions on. SEA-CD-325 World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike
More informationCoding for the Contraceptive Implant and IUDs
LARC Quick Coding Guide 2018 UPDATE Coding for the Contraceptive Implant and IUDs CORRECT CODING can result in more appropriate compensation for services and devices. To help practices receive appropriate
More informationWHO/NMH/TFI/11.3. Warning about the dangers of tobacco. Executive summary. fresh and alive
WHO/NMH/TFI/11.3 WHO REPORT on the global TOBACCO epidemic, 2011 Warning about the dangers of tobacco Executive summary fresh and alive World Health Organization 2011 All rights reserved. Publications
More informationCLINDAMYCIN PALMITATE
February 2018 Document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 CLINDAMYCIN PALMITATE POWDER FOR ORAL
More informationABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)
August 2012 RESTRICTED ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012) Draft for comment This document was provided by a quality control expert. Should you have
More informationNelly Mugo, MBChB, MMed, MPH Kenya Medical Research Institute. May 2015
Nelly Mugo, MBChB, MMed, MPH Kenya Medical Research Institute May 2015 Outline Rationale for the trial Design and objectives Contraceptive methods to be evaluated Study population and follow-up Potential
More informationPhoto Book: Identify Signs of Illness
Integrated Management of Childhood Illness Caring for the Sick Child in the Community Photo Book: Identify Signs of Illness Photo 1 and 2. Chest indrawing Photo 3. Severe malnutrition (marasmus) Photo
More informationLEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT
January 2012 RESTRICTED DRAFT PROPOSAL FOR The International Pharmacopoeia LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS (January 2012) DRAFT FOR COMMENT This document was provided by a quality control expert.
More informationSULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)
September 2010 RESTRICTED SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010) REVISED DRAFT FOR COMMENT This document was provided by a quality
More informationPROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)
July 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012) PROPOSED REVISION FOR COMMENT The background
More informationCYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)
August 2015 Document for comment 1 2 3 4 5 CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA (AUGUST 2015) DRAFT FOR COMMENT 6 Should you have any comments
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationDRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)
August 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010) DRAFT FOR COMMENT This document was provided by a quality control expert and was
More informationThe Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone
More informationEMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED EMTRICITABINE AND TENOFOVIR TABLETS Draft proposal for The International Pharmacopoeia (September2010) REVISED DRAFT FOR COMMENT This document was provided by a quality control
More informationDECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION
DECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION AFRO Library Cataloguing-in-Publication Data Declaration on Acceleration of HIV Prevention efforts in the African Region 1. Acquired
More informationMONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES
MONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES A WHO Library Cataloguing-in-Publication Data Monitoring the building blocks of health systems:
More informationEastern Mediterranean Region Framework for health information systems and core indicators for monitoring health situation and health system
Eastern Mediterranean Region Framework for health information systems and core indicators for monitoring health situation and health system performance 2017 Eastern Mediterranean Region Framework for
More informationIMPLEMENTATION OF THE REVISED GENERAL
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 IMPLEMENTATION OF THE REVISED GENERAL MONOGRAPH ON PARENTERAL
More informationDRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS (August 2010) DRAFT FOR COMMENT This document was provided by a quality control
More informationFertility control: what do women want?
FIAPAC 2018 Fertility control: what do women want? Dr. Raymond H.W. Li MBBS, MMedSC, FRCOG, FHKAM (O&G) Cert RCOG/HKCOG (Reprod Med) Department of O&G, The University of Hong Kong The Family Planning Association
More informationWHO Preferred Product Characteristics for Next-Generation Influenza Vaccines
WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS WHO preferred product characteristics for next generation influenza vaccines
More informationEmergency Contraception THE FACTS
Emergency Contraception Quick Facts What is it? Emergency contraception is birth control that you use after you have had unprotected sex--if you didn t use birth control or your regular birth control failed.
More informationNATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES
NATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES WHO Library Cataloguing-in-Publication data World Health Organization, Regional Office for South-East Asia. National AIDS programme management:
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationDRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS
December 2015 Draft document for comment 1 2 3 4 5 6 DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS (December 2015) REVISED DRAFT FOR COMMENT Should
More informationAnnex 2: GRADE evidence profiles
Annex 2: GRADE evidence profiles GRADE table 1: Does the use of a particular method of hormonal contraception directly increase the risk of HIV acquisition in women? Outcome ( participants) Injectable
More informationManagement of Emergency Contraception (EC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Emergency Contraception (EC) The risks and benefits of an IUD or oral EC should be discussed and documented (see appendix). Reasonable measures
More informationDraft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution
August 2015 Draft document for comment 1 2 3 4 5 6 Draft monograph for inclusion in The International Pharmacopoeia Dextromethorphani solutionum peroralum - Dextromethorphan oral solution (August 2015)
More informationGroup B Streptococcus Vaccine Development Technology
WHO/IVB/17.10 Group B Streptococcus Vaccine Development Technology ROADMAP Priority activities for development, testing, licensure and global availability of Group B streptococcus vaccines 2017 GROUP B
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationBRIEF REPORTS. Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH
Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH BACKGROUND AND OBJECTIVES: Providing long-acting reversible contraception
More informationPublic health relevant virological features of Influenza A(H7N9) causing human infection in China
Public health relevant virological features of Influenza A(H7N9) causing human infection in China Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional
More informationWHO Emergency Risk Communication
WHO Emergency Risk Communication Course Introduction Module A 1 Copyright World Health Organization 2016 All rights reserved The designations employed and the presentation of the material in this publication
More informationZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)
September 2006 RESTRICTED ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006) This document was provided by a contracted quality control laboratory.
More informationIARC Monographs on the Evaluation of Carcinogenic Risks to Humans. VOLUME 93 Carbon Black, Titanium Dioxide, and Talc
WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Monographs on the Evaluation of Carcinogenic Risks to Humans VOLUME 93 Carbon Black, Titanium Dioxide, and Talc LYON, FRANCE 2010
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationWHO / Christopher Black POLICY BRIEF TRANSITIONING TO AN OPTIMAL PAEDIATRIC ARV FORMULARY: IMPLEMENTATION CONSIDERATIONS
WHO / Christopher Black POLICY BRIEF TRANSITIONING TO AN OPTIMAL PAEDIATRIC ARV FORMULARY: IMPLEMENTATION CONSIDERATIONS World Health Organization 2018 Some rights reserved. This work is available under
More informationINTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS
RESTRICTED INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS DRAFT FOR COMMENT Please address any comments you may have on this document, by 12 July 2006, to Dr S. Kopp, Quality Assurance and
More informationJennifer Zeng. Chapel Hill. Summer Daniel Jonas. 7/10/18 Date. Leila Kahwati. 6/29/2018 Date
Effect of Long Acting Reversible Contraceptives on Dual Method Use and Incidence of Sexually Transmitted Infections among Female Adolescents and Young Adults in the United States: A Systematic Review By
More informationIntercountry meeting of national malaria programme managers from countries of HANMAT and PIAM-Net
WHO-EM/MAL/367/E Summary report on the Intercountry meeting of national malaria programme managers from countries of HANMAT and PIAM-Net Muscat, Oman 22 24 September 2011 World Health Organization 2012
More informationDiabetes. Halt the diabetes epidemic
Diabetes Halt the diabetes epidemic WHO Library Cataloguing in Publication Data World Health Organization. Regional Office for the Eastern Mediterranean Diabetes: halt the diabetes epidemic / World Health
More informationRegional Response Plan for TB-HIV
Regional Response Plan for TB-HIV 2017 2021 SEA-TB-370 Regional Response Plan for TB-HIV 2017 2021 Regional Response Plan for TB-HIV 2017 2021. World Health Organization 2017 Some rights reserved. This
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationCUTANEOUS LEISHMANIASIS
CUTANEOUS LEISHMANIASIS Why are you neglecting me? A WHO initiative to control Cutaneous Leishmaniasis in selected Old World areas This document has been produced as the result of a WHO Informal Consultative
More informationReproductive health research at WHO
Reproductive health research at WHO Paul F.A. Van Look, MD PhD Department of Reproductive Health and Research World Health Organization Geneva, 11 March 2004 PVL_GE_StudCourse_MAR04/1 Health is a state
More informationBLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018
BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What
More informationVolume 10 Cervix Cancer Screening
IARC Handbooks of Cancer Prevention Volume 10 Cervix Cancer Screening International Agency For Research On Cancer The International Agency for Research on Cancer (IARC) was established in 1965 by the World
More informationWHO PROTOCOL FOR PERFORMANCE LABORATORY EVALUATION OF HCV SEROLOGY ASSAYS
WHO PROTOCOL FOR PERFORMANCE LABORATORY EVALUATION OF HCV SEROLOGY ASSAYS WHO/EMP/RHT/PQT/2017.xx Page 1 of 15 World Health Organization 2017 Some rights reserved. This work is available under the Creative
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationUnintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use
3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationWHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
More informationClinical Review Report (Sample)
CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text Disclaimer: The information in this document is intended to help Canadian health
More informationSimplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok
Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able
More informationWHO PROTOCOL FOR PERFORMANCE LABORATORY EVALUATION OF HIV SEROLOGY ASSAYS
WHO PROTOCOL FOR PERFORMANCE LABORATORY EVALUATION OF HIV SEROLOGY ASSAYS WHO/EMP/RHT/PQT/2017.xx Page 1 of 17 World Health Organization 2017 Some rights reserved. This work is available under the Creative
More informationRECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON
RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for
More informationSecond intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network
Summary report on the Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network WHO-EM/CSR/070/E Sharm el-sheikh, Egypt 24 27 November 2013 Summary
More informationMaximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community
Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community Reproductive Health 2012 September 21, 2012 David Turok, MD/MPH Objectives Communicate to colleagues the reduction
More informationTECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE
TECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE DECEMBER 2015 TECHNICAL UPDATE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE DECEMBER 2015 WHO Library
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More informationREVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)
August 2010 RESTRICTED REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM (August 2010) DRAFT FOR COMMENT This document was provided by a quality control expert
More informationNinth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries
Summary report on the Ninth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries WHO-EM/MAL/387/E Cairo, Egypt 24 26 October 2017 Summary report on the Ninth intercountry
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #432: Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationContraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital
Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception
More informationLARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures
LARC: Long Acting Reversible Contraception Disclosures I have no relevant financial disclosures Jennifer Kerns, MD, MPH Assistant Professor, UCSF Obstetrics, Gynecology and Reproductive Sciences San Francisco
More informationThe Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH
The Doctor Is In Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH Contraception Resources from the CDC: 2016 U.S. Medical Eligibility Criteria
More informationLEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common
4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationWHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines
WHO/IVB/17.11 WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS Family, Womens s and Children s Health (FWC) This
More informationUpdate on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot
More informationEND HEPATITIS BY 2030 PREVENTION, CARE AND TREATMENT OF VIRAL HEPATITIS IN THE AFRICAN REGION: FRAMEWORK FOR ACTION,
END HEPATITIS BY 2030 PREVENTION, CARE AND TREATMENT OF VIRAL HEPATITIS IN THE AFRICAN REGION: FRAMEWORK FOR ACTION, 2016-2020 ii PREVENTION, CARE AND TREATMENT OF VIRAL HEPATITIS IN THE AFRICAN REGION:
More informationContraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE
Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationA systematic review of some of the side effects of copper T380 intrauterine contraceptive device
A systematic review of some of the side effects of copper T380 intrauterine contraceptive device Ahmed Nehad Ahmed Hatem Askalani IAMANEH Scholarship Reproductive Health Research Course Geneva, 2006 Introduction
More informationSPECIAL DISCLAIMER FOR INTERPRETING SERVICES INVOLVING CALLS TO EMERGENCY SERVICE PROVIDERS (911/E911), OR LEGAL, MEDICAL OR MENTAL HEALTH ISSUES
SPECIAL DISCLAIMER FOR INTERPRETING SERVICES INVOLVING CALLS TO EMERGENCY SERVICE PROVIDERS (911/E911), OR LEGAL, MEDICAL OR MENTAL HEALTH ISSUES Governing Language. The English language version of this
More information